POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11

Christian Fernsby |
EMA has started evaluating an application to extend the use of BioNTech/ fizer’s COVID-19 vaccine, Comirnaty, to children aged 5 to 11.

Article continues below




Comirnaty is a vaccine for preventing COVID-19, currently authorised for use in people aged 12 and older.

It contains a molecule called messenger RNA (mRNA) with instructions for producing a protein, known as the spike protein, which is naturally present in SARS-CoV-2, the virus that causes COVID-19.

The vaccine works by preparing the body to defend itself against SARS-CoV-2. EMA’s human medicines committee (CHMP) will review the data on the vaccine, including results from an ongoing clinical study involving children aged 5 to 11, in order to decide whether to recommend extending its use.

The CHMP’s opinion will then be forwarded to the European Commission, which will issue a final decision.


What to read next

EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty
EMA starts evaluating use of COVID-19 vaccine Comirnaty in young people
EMA evaluating data on booster dose of COVID-19 vaccine Spikevax